ID

14490

Descripción

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00639691

Link

https://clinicaltrials.gov/show/NCT00639691

Palabras clave

  1. 18/4/16 18/4/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

18 de abril de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :


Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Asthma NCT00639691

Eligibility Asthma NCT00639691

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00639691
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female, ≥ 6years of age;
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
who have a diagnosis of allergic asthma ≥ 1 year duration according to american thoracic society (ats) criteria;
Descripción

allergic asthma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0155877
UMLS CUI [1,2]
C0040223
severe persistent allergic asthma who remain symptomatic despite optimal therapy (as per canadian asthma consensus report (1999));
Descripción

severe persistent allergic asthma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1960048
UMLS CUI [1,2]
C0155877
subjects having successfully completed one of the following protocols: cige025a011e3, cige025a2425, cige025aia05;
Descripción

subjects having successfully completed one of the following protocols: cige025a011e3, cige025a2425, cige025aia05;

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
elevated immunoglobin e levels
Descripción

IgE level

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2229760
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
significant systemic disease
Descripción

comorbidity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
pregnancy or lactation
Descripción

pregnancy or lactation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
an active lung disease other than allergic asthma (eg: cystic fibrosis, bronchiestasis);
Descripción

lung disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0024115
history of food or drug related severe anaphylactoid or anaphylactic reaction(s);
Descripción

anaphylactoid or anaphylactic reaction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0340865
UMLS CUI [2]
C0002792
current treatment with warfarin (coumadin®), immunomodulatory therapy (e.g., methotrexate, gold, cyclosporine), or antiplatelet therapy.
Descripción

warfarin immunomodulatory therapy or antiplatelet therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0043031
UMLS CUI [2]
C1963758
UMLS CUI [3]
C1096021

Similar models

Eligibility Asthma NCT00639691

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00639691
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
age
Item
male or female, ≥ 6years of age;
boolean
C0001779 (UMLS CUI [1])
allergic asthma
Item
who have a diagnosis of allergic asthma ≥ 1 year duration according to american thoracic society (ats) criteria;
boolean
C0155877 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
severe persistent allergic asthma
Item
severe persistent allergic asthma who remain symptomatic despite optimal therapy (as per canadian asthma consensus report (1999));
boolean
C1960048 (UMLS CUI [1,1])
C0155877 (UMLS CUI [1,2])
subjects having successfully completed one of the following protocols: cige025a011e3, cige025a2425, cige025aia05;
Item
subjects having successfully completed one of the following protocols: cige025a011e3, cige025a2425, cige025aia05;
boolean
C2348568 (UMLS CUI [1])
IgE level
Item
elevated immunoglobin e levels
boolean
C2229760 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
comorbidity
Item
significant systemic disease
boolean
C0009488 (UMLS CUI [1])
pregnancy or lactation
Item
pregnancy or lactation
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
lung disease
Item
an active lung disease other than allergic asthma (eg: cystic fibrosis, bronchiestasis);
boolean
C0024115 (UMLS CUI [1])
anaphylactoid or anaphylactic reaction
Item
history of food or drug related severe anaphylactoid or anaphylactic reaction(s);
boolean
C0340865 (UMLS CUI [1])
C0002792 (UMLS CUI [2])
warfarin immunomodulatory therapy or antiplatelet therapy
Item
current treatment with warfarin (coumadin®), immunomodulatory therapy (e.g., methotrexate, gold, cyclosporine), or antiplatelet therapy.
boolean
C0043031 (UMLS CUI [1])
C1963758 (UMLS CUI [2])
C1096021 (UMLS CUI [3])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial